|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.85 TWD | -0.22% |
|
-1.61% | -25.69% |
| 07-13 | EirGenix Partner Secures EMA Nod for Breast Cancer Biosimilar Vial | MT |
| 05-27 | Transcenta Secures 7 Million Yuan Milestone Payment Under EirGenix Bio-Platform Deal; Shares Fall 7% | MT |
| Market Cap | 13.89B 429M 377M 352M 323M 604M 41.05B 619M 4.17B 1.63B 20.31B 1.61B 1.57B 70.22B | P/E 2026 * |
-30.2x | P/E 2027 * | 80.4x |
|---|---|---|---|---|---|
| Enterprise Value | 12.64B 390M 343M 320M 294M 550M 37.36B 563M 3.79B 1.48B 18.49B 1.46B 1.43B 63.92B | EV / Sales 2026 * |
8.58x | EV / Sales 2027 * | 5.57x |
| Free-Float |
60% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -0.22% | ||
| 1 week | -1.61% | ||
| Current month | -8.12% | ||
| 1 month | -4.88% | ||
| 3 months | -2.65% | ||
| 6 months | -27.57% | ||
| Current year | -25.69% |
| 1 week | 45.05 |  | 47.45 |
| 1 month | 44.3 | | 53.6 |
| Current year | 40.15 | | 67.6 |
| 1 year | 40.15 | | 84.3 |
| 3 years | 40.15 | | 111 |
| 5 years | 40.15 | | 163.5 |
| 10 years | 21.55 | | 195 |
| Manager | Title | Age | Since |
|---|---|---|---|
Li Cheng Liu
CEO | Chief Executive Officer | - | 31/03/2013 |
Hsiu Chuan Yang
DFI | Director of Finance/CFO | - | 02/05/2016 |
Yu Wen Liu
PRN | Corporate Officer/Principal | - | 19/05/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Cheng Yue Cheng
BRD | Director/Board Member | - | 13/06/2013 |
Ming Hsien Chen
BRD | Director/Board Member | - | 12/09/2016 |
Fu Hsiu Yin
BRD | Director/Board Member | - | 12/09/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.22% | -1.61% | -29.46% | -56.75% | 429M | |
| +0.03% | +6.79% | +24.59% | -6.79% | 70.75B | |
| -8.33% | -5.43% | +23.95% | +185.39% | 54.35B | |
| -4.52% | +47.90% | +47.90% | +47.90% | 47.19B | |
| -0.11% | +10.52% | -52.81% | -52.36% | 42.48B | |
| +1.76% | +5.81% | +63.59% | -21.11% | 30.91B | |
| -2.18% | +9.77% | +64.26% | +101.46% | 25.76B | |
| -2.36% | -6.16% | +66.84% | -54.08% | 21.62B | |
| -1.67% | -2.97% | -10.26% | +155.35% | 19.91B | |
| -2.35% | +1.06% | +80.35% | +142.71% | 16.33B | |
| Average | -1.99% | +3.40% | +27.90% | +44.17% | 32.97B | |
| Weighted average by Cap. | -2.41% | +4.91% | +27.96% | +47.99% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.47B 45.49M 39.97M 37.31M 34.24M 64.1M 4.36B 65.68M 442M 173M 2.16B 171M 167M 7.45B | 2.34B 72.31M 63.54M 59.31M 54.43M 102M 6.93B 104M 703M 275M 3.43B 271M 266M 11.85B |
| Net income | -458M -14.13M -12.42M -11.59M -10.64M -19.92M -1.35B -20.41M -137M -53.76M -670M -53.07M -51.91M -2.32B | 172M 5.31M 4.66M 4.35M 4M 7.48M 508M 7.66M 51.63M 20.19M 252M 19.93M 19.5M 870M |
| Net Debt | -1.25B -38.48M -33.81M -31.56M -28.97M -54.22M -3.69B -55.56M -374M -146M -1.82B -144M -141M -6.31B | -838M -25.86M -22.72M -21.21M -19.47M -36.44M -2.48B -37.34M -252M -98.36M -1.23B -97.1M -94.99M -4.24B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/07/26 | NT$45.85 | -0.22% | 895,295 |
| 28/07/26 | NT$45.95 | -2.34% | 450,163 |
| 27/07/26 | NT$47.05 | +3.18% | 624,959 |
| 24/07/26 | NT$45.60 | 0.00% | 276,811 |
| 23/07/26 | NT$45.60 | -2.15% | 448,098 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 6589 Stock
Select your edition
All financial news and data tailored to specific country editions
